AstraZeneca PLC on Wednesday said Non-Executive Director Bruce Burlington will retire from the board on August 31.
The FTSE 100-listed pharmaceutical said Burlington, who joined the board in 2010, will also step down as a member of the audit committee, the nomination and governance committee and from his role as chairman of the science committee.
Chairman Leif Johansson said: “Bruce has been an exemplary director who has made a significant contribution to the board’s work over many years. We have valued his insightful and frank participation as a board member, and chairman of the science committee during a period of innovation-led transformation at AstraZeneca.
“His diligence and commitment to the work of the audit committee and the nomination and governance committee should also be acknowledged.”
By Maryam Cockar
Source: Alliance News
Big Pharma has long seen the potential for AI and machine learning to accelerate drug development. But Novo Nordisk is going a step further by channeling $200 million toward the creation of a computer that will outrun anything in existence.
Current methods for diagnosing Alzheimer’s disease rely on a complex combination of self- and caregiver-reported symptoms, a physical examination and either a PET scan or a spinal tap to look for evidence of amyloid plaque build-ups in the brain. But a new artificial intelligence-based method may make the diagnostic process a much more objective one.
There is lots of talk about diversity and inclusion in business, including in pharma and medtech. A new report by the Open Political Economy Network (OPEN), a think tank focusing on migration and diversity, released its “Minority Businesses Matter: Europe” report highlighting the successes and challenges of ethnic minority-owned businesses in Europe.